• NTC's Technology

    NTC's Technology

    Autolysis Technology

     

    Microbial strains have been created at NTC for simplified purification of recombinant products, such as plasmid DNA and recombinant protein therapeutics. This eliminates the need for complicated chemical or physical methods of cell cracking. [Patent Ref: PCT/US05/28870; PCT/08/06553]

     

    HyperGRO™ Fermentation Process: Record Yields for Plasmid DNA Production

     

    NTC’s HyperGRO™ fermentation process and media are used routinely for production of gene therapy vectors and DNA vaccines.  Improvements in fed-batch fermentation resulted in plasmid DNA yields of >2.2g/L. [Patent Ref: PCT/US05/29238]

     

    Recombinant Protein Production (E. coli)

     

    NTC’s pVEX™ system is arguably the most advanced E. coli recombinant protein production suite available in the industry today, capable of protein yields routinely in the range of 2-20g/L.

     

    Genome Mass Transfer (GMT™) Strain Engineering Technology

     

    GMT is a disruptive NTC technology, which facilitates the transfer of desirable traits freely between strains. The strategy is to directly transfer genomic DNA from a strain with a desired property into a recipient strain that expresses recombineering genes. GMT replaces older technology, such as phage P1 transduction. For example, genomic DNA becomes efficiently integrated into the recipient host genome through homologous recombination, after transfer, for example, by electroporation. In some cases, amplified DNA is transferred directly from cell lysates, dramatically simplifying the task of genome engineering. [Patent Ref: PCT/US08/06548]

     

    DNA Vaccination Technology

     

    DNA vaccines have been improved through the introduction of NTC’s RNA elements technology (RNAe), redirecting the innate immune response through alteration of pattern recognition elements.  NTC’s pDNAVACCUltra vectors are designed for: rapid deployment, multi-mode presentation, enhanced expression, enhanced production yield, and antibiotic-free selection. [Patent Ref: PCT/US06/02174; PCT/US08/06554]

     

    Retro-Vector Technology

     

    NTC currently is focusing 100% on non-viral vectors and will consider divesting/licensing this technology. Retro-vectors, derived from retroviruses, are among the most ubiquitous of reagents used for gene therapy research.  NTC’s retro-vector technologies include: Retrotransposons (US 6,4100,220; US5,879,933); Vectors for gene transfer (US6,027,722; 6,287,863); Self-assembling genes (US 6,410,220); and Viral packaging signal without gag gene sequences (US 6,573,091).

     

     

  • Consulting

    Consulting

    Consulting services

     

    NTC scientists are available to assist you with project development.

     

    Services include:

    Insert design

    Assistance with preparing regulatory documents

    Experimental design

     

     

    Basic consulting is included with products and services, whereas problem solving, advanced product design, regulatory writing and tech transfer are available at NTC's  listed rates.

  • Partnering Opportunities: Gene Therapeutics and DNA Vaccines

    Partnering Opportunities:

    Gene Therapeutics and DNA Vaccines Development

     

    NTC is a leader in non-viral vector development, providing key enabling technologies for direct DNA therapies, including:

     

    • Enhanced mammalian plasmid expression vectors

     

    • RIG-I mediated innate immunity activation for DNA vaccines

     

    • Advanced host strains for modulating pDNA methylation

     

    • Antibiotic free plasmid propagation

     

    • PAS-BH highest copy plasmid replicon for superior,

    economical production in E. coli

     

    • Translational enhancers

     

    • Improved promoters

     

    • Antisilencing elements

     

    • Regulatory compliant vectors

     

    • HyperGRO fermentation process for highest production

    yields in E. coli

     

     

    NTC is seeking partners with lead therapeutic and immunologic targets and/or novel delivery systems. NTC will provide vectors with partners’ genes of choice, fully optimized, constructed and purified, ready for preclinical use in animals - in about a month.

     

     

    Call NTC today to discuss your upcoming biopharmaceutical development projects.

     

    NTC Contact:

    Phone: (402) 323-6289 (natx)

    Fax: (402) 323-6292

     

     

  • Partnering Opportunities: Genome Masss Transfer

    Partnering Opportunities:

    Advanced Strains of Microorganisms for Biopharmaceutical and Industrial Production

     

    GMT is a disruptive NTC technology, which facilitates orderly and predictable transfer of desirable traits between strains. The strategy is to directly transfer genomic DNA from a strain with a desired property into a recipient strain that expresses recombineering genes. It is not necessary to amplify or isolate DNA. GMT replaces older technology, such as phage P1 transduction. For example, genomic DNA becomes efficiently integrated into the recipient host genome through homologous recombination, after transfer, for example, by electroporation. In some cases, amplified DNA is transferred directly from cell lysates, dramatically simplifying the task of genome engineering. [Patent Ref: PCT/US08/06548]

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Call NTC today to discuss your upcoming biopharmaceutical development projects.

     

    NTC Contact:

    Phone: (402) 323-6289 (natx)

    Fax: (402) 323-6292

     

    1) Cells are made competent for mass transfer

     

    Cells are ready for genome mass transfer
    Competent cells are incubated with DNA.
    DNA incubated with competent cells take up the DNA.
    The transfected DNA taken up by the cells associates with the nucleoplasm.
    The donor DNA integrates into cellular genomic DNA and replication takes place.
    The newly integrated and replicated DNA begins to form two cells.
    Cells bearing integrated foreign DNA divide.
    Cells resulting from DNA integration are grown on selection media to generate colonies of transfected cells.

    2) Add DNA

     

    8) Selection to grow out recombinant strains

    7) Cell division

    6) Assimilation and septation

     

    5) Donor DNA integration and replication

     

    3) DNA is transfected into cells

     

    4) DNA associates with nucleoplasm

     

  • IP Licensing

    IP Licensing

    Improved Plasmid DNA Fermentation

     

    Fermentation patent: High yield HyperGRO, fed-batch fermentation process, maximum yields 2.5g/l: PROCESS FOR PLASMID DNA FERMENTATION: PCT/US2005/29238

     

    Autolysis: (divisional) relating to: low temperature glycerol stock; and post fermentation hold:  IMPROVED E COLI PLASMID PRODUCTION STRAINS: PCT/US2008/006553

     

    Anti-insert stabilization of toxic plasmid inserts: BACTERIAL STRAINS WITH IMPROVED PLASMID STABILITY: US61/210,073

    Improved Vectors

     

    Improved DNA vaccines: VECTORS AND METHODS FOR GENETIC IMMUNIZATION: PCT/US2008/006554, including: RIG-1; antibiotic free plasmids; chimeric promoter

     

        1. Type 1 interferon induction via MDA5 activation via VARNA or a derivative

     

        2.  Method of improving the immune response via Type 1 interferon by expression of immunostimulatory dsRNA from a DNA vaccine

     

        3. Method of improving the immune response by including in a DNA vaccine vector a mitochondrial R region

     

        4. Method of production of markerless, antibiotic free plasmids using RNA-IN, RNA-OUT antisense technology

     

        5. An improved eukaryotic promoter comprising CMV and SV40 sequences

     

        Improved plasmid Copy number – PAS-BH and SV40: DNA PLASMIDS WITH IMPROVED COPY NUMBER

     

        Improved DNA vaccines – RIG-1 Activation of innate immune responses: VECTORS AND METHODS OF GENETIC IMMUNIZATION: PCT/US2006/02174

     

        Anti-silencing elements (ASE): Allow prolonged expression of genes after transient or integrated expression: EUKARYOTIC EXPRESSION VECTORS RESISTANT TO TRANSGENE SILENCING: Serial No.:  US61/342,273

     

        Bacterial strains with Improved plasmid stability

        Gene Silencing Vectors:

     

        1. Plasmids, shUT DOWN™ transient expression vectors

     

        2. siLENTC™, retroviral vectors

    Improved Downstream Processing of Plasmids

     

    Trade secrets: re: downstream processing

     

    Autolysis: improved, non-alkaline lysis-based  plasmid extraction methods and strains: IMPROVED E COLI PLASMID PRODUCTION STRAINS: PCT/US2008/006553

    Protein Manufacturing Platform

     

    pVEX  E. coli high-yield recombinant protein production vectors and process: high yield (typically 1-20g/L); fusion tags

     

    Thermostable adjuvant and thermostable antigen: maltodextrin binding protein (MBP)/flagellin/antigen promotes recombinant antigen extraction, solubilization, and immune responses: THERMOSTABLE FUSION PROTEINS AND THERMOSTABLE ADJUVANT: Serial No.: US61/199651

     

    Defined media fermentation

     

    Autolysis – protein extraction: IMPROVED E COLI PLASMID PRODUCTION STRAINS: PCT/US2008/006553

VECTORS & CELL LINES

Nanoplasmids™

RNA-OUT Retrofit
Mammalian Expression Vectors

Antibiotic Free Vectors

DNA Vaccines

Rig-I Activating Vectors

Recombineering Vectors

pVEX™- E. coli Expression Vector

Anti-Silencing Elements

Gene Silencing

Transient

Retroviral, stable

Cell Lines

Autolytic E. coli Cell Lines

dcm- Strains

 

PLASMID MANUFACTURING

HyperGRO™, E. coli Cell paste

Contract Plasmid Manufacturing

Small Scale Large Scale

Additional Testing

Order Form

Linear Vectors

 

CLONING SERVICES & QC

Rapid VACC™ Precision Cloning

Plasmid Detox Services

Contract QC

Vector Retrofit Services

Swap Marker or Promoter

E. coli Genomic DNA Testing

Residual RNA qPCR

Residual RNA gel

Supercoil Assay

Lymulus Endotoxin Testing

 

PROTEIN PRODUCTS

Thermostable Protein Expression

HN-Flagellin Protein

HN-TST-HA2 Protein

HN-TST-Flagellin Protein

HYPERTAQ™ DNA Polymerase

Custom Recombinant Proteins

Fluorescent Proteins

TECHNOLOGY & CONSULTING

Process Development

Plasmid Fermentation & Purification

Protein Fermentation & Purification

High yield plasmid Fermentation

ABOUT NTC

Patents

Publications

Management Team

Board

Investor Information